{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-131263","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.663789+00:00","generated_at":"2026-05-29T13:28:33.873126+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agenus secures $22M mortgage and announces realignment: 60% cost cut, FY25 cash burn ~$100M","bullets":["$22M non-amortizing mortgage backed by Berkeley CMC facility and Vacaville land; net proceeds $20M after costs and reserve.","Interest 12% Year 1, 13% Year 2, paid 50% cash and 50% common stock; 153,003 shares issued as first month interest and fees.","Strategic Operational Realignment: 60% reduction in external expenditures; CMC transitioned to fee-for-service business.","FY 2025 cash burn projected at ~$100M, pending finalization of additional strategic transactions.","Focus on botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer for late-stage development and registration pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-131263","json":"https://secwatch.observer/filing/0000950170-24-131263.json","markdown":"https://secwatch.observer/filing/0000950170-24-131263.md","text":"https://secwatch.observer/filing/0000950170-24-131263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024131263/0000950170-24-131263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024131263/agen-20241126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T13:28:33.873126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}